Group One Trading’s TG Therapeutics TGTX Stock Holding History

Group One Trading’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.99M	Sell	90,100 -36,400	-29%	-$1.08M	0.01%	1710
2025 Q4	$3.77M	Sell	126,500 -42,300	-25%	-$1.38M	0.01%	1746
2025 Q3	$6.1M	Buy	168,800 +17,200	+11%	+$567K	0.01%	1315
2025 Q2	$5.46M	Sell	151,600 -40,900	-21%	-$1.52M	0.01%	1267
2025 Q1	$7.59M	Sell	192,500 -101,100	-34%	-$3.4M	0.02%	781
2024 Q4	$8.84M	Buy	293,600 +135,300	+85%	+$3.88M	0.02%	780
2024 Q3	$3.7M	Sell	158,300 -55,400	-26%	-$1.21M	0.01%	1238
2024 Q2	$3.8M	Sell	213,700 -59,200	-22%	-$945K	0.01%	981
2024 Q1	$4.15M	Sell	272,900 -312,600	-53%	-$4.98M	0.02%	947
2023 Q4	$10M	Buy	585,500 +224,800	+62%	+$2.61M	0.03%	707
2023 Q3	$3.02M	Buy	360,700 +199,500	+124%	+$2.78M	0.01%	1306
2023 Q2	$4M	Buy	161,200 +75,700	+89%	+$1.96M	0.01%	1141
2023 Q1	$1.29M	Sell	85,500 -723,800	-89%	-$11M	﹤0.01%	1920
2022 Q4	$9.57M	Buy	809,300 +365,800	+82%	+$2.65M	0.02%	761
2022 Q3	$2.63M	Sell	443,500 -116,100	-21%	-$761K	0.01%	1671
2022 Q2	$2.38M	Sell	559,600 -345,100	-38%	-$2.15M	﹤0.01%	1888
2022 Q1	$8.6M	Sell	904,700 -88,000	-9%	-$1.02M	0.01%	1105
2021 Q4	$18.9M	Buy	992,700 +79,500	+9%	+$2.06M	0.02%	711
2021 Q3	$30.4M	Buy	913,200 +103,700	+13%	+$3.21M	0.03%	428
2021 Q2	$31.4M	Buy	809,500 +3,300	+0.4%	+$130K	0.04%	399
2021 Q1	$38.9M	Sell	806,200 -49,200	-6%	-$2.36M	0.06%	299
2020 Q4	$44.5M	Buy	855,400 +381,500	+81%	+$12.9M	0.08%	213
2020 Q3	$12.7M	Buy	473,900 +83,800	+21%	+$1.93M	0.04%	425
2020 Q2	$7.6M	Buy	390,100 +136,200	+54%	+$2.19M	0.04%	569
2020 Q1	$2.5M	Buy	253,900 +120,400	+90%	+$1.52M	0.02%	899
2019 Q4	$1.48M	Buy	133,500 +44,800	+51%	+$341K	0.01%	1539
2019 Q3	$498K	Buy	88,700 +12,700	+17%	+$88.5K	﹤0.01%	2336
2019 Q2	$657K	Buy	76,000 +26,500	+54%	+$200K	0.01%	1897
2019 Q1	$398K	Sell	49,500 -125,800	-72%	-$680K	﹤0.01%	2130
2018 Q4	$719K	Sell	175,300 -129,700	-43%	-$645K	0.01%	1747
2018 Q3	$1.71M	Buy	305,000 +121,600	+66%	+$1.39M	0.01%	1282
2018 Q2	$2.41M	Sell	183,400 -34,100	-16%	-$469K	0.02%	1000
2018 Q1	$3.09M	Buy	217,500 +53,400	+33%	+$682K	0.03%	723
2017 Q4	$1.35M	Buy	164,100 +53,700	+49%	+$469K	0.01%	1470
2017 Q3	$1.31M	Sell	110,400 -41,500	-27%	-$473K	0.01%	1366
2017 Q2	$1.53M	Buy	151,900 +12,400	+9%	+$139K	0.02%	1137
2017 Q1	$1.63M	Buy	139,500 +133,700	+2,305%	+$960K	0.02%	1002
2016 Q4	$27K	Buy	5,800 +800	+16%	+$4.69K	﹤0.01%	3578
2016 Q3	$39K	Sell	5,000 -1,500	-23%	-$9.65K	﹤0.01%	3485
2016 Q2	$39K	Sell	6,500 -6,000	-48%	-$48.8K	﹤0.01%	3452
2016 Q1	$107K	Sell	12,500 -44,400	-78%	-$389K	﹤0.01%	2776
2015 Q4	$679K	Sell	56,900 -57,200	-50%	-$722K	0.01%	1585
2015 Q3	$1.15M	Buy	114,100 +42,100	+58%	+$627K	0.02%	1142
2015 Q2	$1.19M	Buy	72,000 +4,200	+6%	+$66.5K	0.02%	1079
2015 Q1	$1.05M	Sell	67,800 -8,300	-11%	-$126K	0.02%	1041
2014 Q4	$1.21M	Buy	76,100 +37,600	+98%	+$490K	0.02%	955
2014 Q3	$411K	Buy	38,500 +27,900	+263%	+$259K	0.01%	1767
2014 Q2	$100K	Buy	10,600 +3,500	+49%	+$22.4K	﹤0.01%	2990
2014 Q1	$49K	Buy	7,100 +2,100	+42%	+$12.4K	﹤0.01%	3645
2013 Q4	$20K	Buy	+5,000	New	+$20.2K	﹤0.01%	4240

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Group One Trading's TGTX Position: Q1 2026 in Review

Group One Trading reduced its TG Therapeutics (TGTX) stake by 80% in Q1 2026, selling an estimated $5.46M and leaving 45,240 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Group One Trading first reported a position in TGTX in Q4 2013 and has held it in 49 quarters since. The position peaked at $56.3M in Q3 2021. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Group One Trading held 45,240 shares of TG Therapeutics worth $1.5M as of Q1 2026.
Group One Trading sold 183,267 TG Therapeutics shares in Q1 2026, an estimated $5.46M.
TG Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2337 holding.
Group One Trading first reported a position in TG Therapeutics in Q4 2013 and has held it in 49 quarters since.
Group One Trading's TG Therapeutics position peaked at $56.3M in Q3 2021.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.